Consensus Omnicell, Inc.

Stocks

OMCL

US68213N1090

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 21:00:00 02/09/2026 BST			5-day change	1st Jan Change
34.71 ^USD	+0.58%		+3.77%	-23.38%

08-14	US Physical Therapy Names Nchacha Etta as Chief Financial Officer	MT
08-05	Tranche Update on Omnicell, Inc.'s Equity Buyback Plan announced on May 22, 2025.	CI

Evolution of the Average Target: Omnicell, Inc.

Evolution of the Target Price: Omnicell, Inc.

Changes in Analyst Recommendations: Omnicell, Inc.

29ea75b3b41a8515eba7a5.dUXoy7WvsV2ytHpuCo_zffKhZi0TPUqOddrBCAC--8Q.R329r-zw8zSA4QkqOfrGTbXHCUQiVH75Irz3MUbzvqA_IL2l583Ibd6BQg~5dacb87c2ff522bacf53b72281694468

Analysts' recommendations: Omnicell, Inc.

02-04	BofA Upgrades Omnicell to Buy From Neutral	MT
01-08	Omnicell Shares Rise After KeyBanc Upgrade	MT
01-08	KeyBanc Upgrades Omnicell to Overweight From Sector Weight, $60 Price Target	MT
23/05/25	Piper Sandler Adjusts Omnicell Price Target to $57 From $46, Maintains Overweight Rating	MT
14/05/25	Wells Fargo Upgrades Omnicell to Overweight From Equal Weight, Adjusts Price Target to $35 From $31	MT
06/01/25	BofA Securities Adjusts Price Target on Omnicell to $46 From $54	MT
31/10/24	BofA Securities Downgrades Omnicell to Neutral From Buy, Adjusts Price Target to $57 From $44	MT
02/08/24	Barclays Upgrades Omnicell to Equalweight From Underweight, Adjusts Price Target to $39 From $26	MT
09/02/24	Wells Fargo Adjusts Price Target on Omnicell to $26 From $28, Maintains Equal-Weight Rating	MT
03/11/23	Piper Sandler Upgrades Omnicell to Overweight From Neutral, Cuts Price Target to $39 From $70	MT
03/11/23	BTIG Downgrades Omnicell to Neutral From Buy	MT
03/11/23	Wells Fargo Upgrades Omnicell to Equal-Weight From Underweight, Adjusts Price Target to $28 From $39	MT
11/10/23	KeyBanc Downgrades Omnicell to Sector Weight From Overweight, Cites 'More Muted' Outlook for Top, Bottom Lines	MT
03/10/23	Benchmark Cuts Price Target on Omnicell to $70 From $88, Maintains Buy Rating	MT
26/09/23	Wells Fargo Adjusts Omnicell Price Target to $39 From $56, Maintains Underweight Rating	MT
04/08/23	KeyBanc Adjusts Price Target on Omnicell to $75 From $80, Maintains Overweight Rating	MT
02/08/23	Piper Sandler Downgrades Omnicell to Neutral From Overweight, Adjusts Price Target to $70 From $66	MT
20/07/23	Wells Fargo Downgrades Omnicell to Underweight From Overweight, Cuts Price Target to $56 From $65	MT
13/07/23	KeyBanc Adjusts Price Target on Omnicell to $80 From $70, Maintains Overweight Rating	MT
15/06/23	Benchmark Capital Adjusts Omnicell Price Target to $88 From $68, Maintains Buy Rating	MT
03/05/23	KeyBanc Adjusts Price Target on OOmnicell MCL to $70 From $65, Maintains Overweight Rating	MT
02/03/23	KeyBanc Adjusts Price Target on Omnicell to $65 From $70, Keeps Overweight Rating	MT
27/02/23	Benchmark Upgrades Omnicell to Buy From Hold, Price Target is $68	MT
02/02/23	KeyBanc Adjusts Price Target on Omnicell to $70 From $75, Maintains Overweight Rating	MT
27/01/23	Piper Sandler Adjusts Omnicell's Price Target to $66 From $55, Keeps Overweight Rating	MT

More recommendations

Medical Software & Technology Services

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
OMNICELL, INC.			+66.69%
VEEVA SYSTEMS INC.			+5.15%
PRO MEDICUS LIMITED			+17.43%
SECTRA AB			+18.72%
HEARTFLOW, INC.			-13%
GENERATE BIOMEDICINES, INC.			+65.85%
XUNFEI HEALTHCARE TECHNOLOGY CO., LTD.	-		+51.02%
ARBUTUS BIOPHARMA CORPORATION	-	-	+7.84%
B-SOFT CO.,LTD.			+68.3%
Average			+32.00%
Weighted average by Cap.			+11.64%